- Fibrinolytic Agents
- Accession Number
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
- ATC Classification
Drug Drug Description Alteplase A recombinant form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli. Reteplase A purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli. Anistreplase A form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli. Tenecteplase A modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli. Drotrecogin alfa A form of recombinant activated human protein C used to reduce mortality in patients with severe sepsis by inhibiting coagulation Factors V and VIII. Defibrotide A mixture of single-stranded oligonucleotides used in the treatment of severe hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation. Ancrod An anticoagulant purified from the venom of the Malayan pit viper that functions by inactivating circulating plasma fibrinogen. Not currently approved for use or marketed in any country. Sulodexide Sulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis, including intermittent claudication, peripheral arterial occlusive disease and post-myocardial infarc-tion. Also investigated... Danaparoid A heparinoid with anticoagulant and antithrombotic activities used for the treatment of acute episode of Heparin-Induced Thrombocytopenia (HIT), and for prophylaxis in patients with a history of HIT. Dalteparin A low molecular weight heparin used for the prophylaxis of thrombotic events in certain patients and prevent acute cardiac ischemic events in patients with unstable angina and non-Q-wave myocardial infarction. Tinzaparin A low molecular weight heparin used for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin. Protein C A medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis. Brinase Not Annotated Saruplase Not Annotated Streptokinase A purified fibrinolytic bacterial protein used to breakdown thrombosis in myocardial infarction, pulmonary embolism, and venous thromboembolism. Desmoteplase Investigated for use/treatment in cerebral ischemia and strokes. Fibrinolysin Fibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas. Astaxanthin Investigated for use/treatment in eye disorders/infections, cancer/tumors (unspecified), and asthma. Urokinase A low molecular weight form of human urokinase used to treat pulmonary embolism and myocardial infarction as well as to clear IV lines. Abciximab A monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention. Dicoumarol For decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis. Argatroban A synthetic direct thrombin inhibitor used for the prevention and treatment of thrombosis related to heparin use. Iloprost A synthetic prostacyclin analog indicated to treat pulmonary arterial hypertension (PAH). Amediplase Investigated for use/treatment in myocardial infarction and thrombosis. Fondaparinux An anticoagulant used to prevent venous thromboembolism, to treat deep vein thrombosis, and to improve survival following myocardial infarction. Edoxaban A novel oral anticoagulant used for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Monteplase Monteplase has been used in trials studying the treatment of Pulmonary Embolism. Ferric chloride Not Annotated
- Drugs & Drug Targets